Early versus late pulmonary rehabilitation (PR) following treatment for inoperable nonsmall cell lung cancer (NSCLC)

V. Shannon, J. Maldonado, C. Thurman (Houston, United States Of America)

Source: Annual Congress 2013 –The best abstracts in extra-pulmonary features and pulmonary rehabilitation
Session: The best abstracts in extra-pulmonary features and pulmonary rehabilitation
Session type: Oral Presentation
Number: 4855
Disease area: Airway diseases

Congress or journal article abstractSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Shannon, J. Maldonado, C. Thurman (Houston, United States Of America). Early versus late pulmonary rehabilitation (PR) following treatment for inoperable nonsmall cell lung cancer (NSCLC). Eur Respir J 2013; 42: Suppl. 57, 4855

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of a pulmonary rehabilitation programme (PRP) after lung resection (LR) for cancer
Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention
Year: 2005


A prospective study of survival after surgery for early stage non-small cell lung cancer in patients with COPD
Source: International Congress 2015 – Risk assessment and prevention of complications in thoracic surgery
Year: 2015



Use of Bode index (BI) in patients with COPD undergoing inpatient pulmonary rehabilitation (IPR) after lung resection (LR) for non small cell lung cancer (NSCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 70s
Year: 2006

The impact of chronic obstructive pulmonary disease on survival of the patients with small-cell lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015


Two-stage treatment of non-small cell lung cancer (NSCLC) in patients with severe coronary heart disease.
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019

Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care.
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019

Prognostic affect of the chronic obstructive pulmonary disease on the local-advanced stage non-small cell lung cancer
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014

Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Source: ERS webinar 2021: Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Year: 2021


Stereotactic body radiation does not impair respiratory health in patients with stage I non-small cell lung cancer
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013


Treatment of early (stage I/II) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005


Mortality in asymptomatic vs. symptomatic patients surgically treated for non-small cell lung cancer (NSCLC)
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013


Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013


Lobectomy at patients with lung cancer and a chronic obstructive pulmonary disease as analogue of lung volume reduction surgery in COPD patients: To do or not to do?
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013

Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019


Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC).
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017



Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002

LATE-BREAKING ABSTRACT: Early relapse of non-small cell lung cancer (NSCLC) found after CNS-symptoms
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016


Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006


Effects of a combination of pulmonary rehabilitation (PR) and non invasive ventilation (NIV) in patients with advanced interstitial lung disease (ILD)
Source: Annual Congress 2009 - Noninvasive ventilation in chronic respiratory failure
Year: 2009


Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008